Evidence map›Paper›PMID 37347406›Full record

ArticleAdvances in therapy2023

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Thomas Bieber, Eugen Feist, Alan D Irvine, Masayoshi Harigai, Ewa Haladyj, Susan Ball, Walter Deberdt, Maher Issa, Susanne Grond, Peter C Taylor

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Thomas BieberDepartment of Dermatology and Allergy, University of Bonn, Bonn, Germany.
Eugen FeistDepartment of Rheumatology, Helios Clinic Vogelsang-Gommern, Cooperation Partner of the Otto-Von-Guericke University, Sophie-von-Boetticher-Straße 1, Vogelsang-Gommern, 39245, Germany.
Alan D IrvineClinical Medicine, Trinity College Dublin, Dublin, Ireland.
Masayoshi HarigaiDivision of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Ewa HaladyjEli Lilly and Company, Indianapolis, IN, USA.
Susan BallEli Lilly and Company, Indianapolis, IN, USA.
Walter DeberdtEli Lilly and Company, Indianapolis, IN, USA.
Maher IssaEli Lilly and Company, Indianapolis, IN, USA.
Susanne GrondEli Lilly and Company, Indianapolis, IN, USA.
Peter C TaylorThe Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.ORCID http://orcid.org/0000-0001-7766-6167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37347406
PMCPMC10427552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.